Robert Orlowski

Robert Orlowski is a leading myeloma researcher at MD Anderson Cancer Center specializing in rational drug combinations and the development of novel agents for myeloma. He contributed to the development of panobinostat as an HDAC inhibitor in myeloma and has led multiple early-phase clinical trials investigating new drug combinations. His research focuses on identifying synergistic combinations that overcome drug resistance in relapsed and refractory myeloma. He is a principal investigator in multiple ongoing Phase 1/2 myeloma trials.